Alzheimer's agitation drug passes early safety check
NCT ID NCT05227118
First seen May 01, 2026 · Last updated May 04, 2026 · Updated 1 time
Summary
This early-stage study tested a new drug called MK-8189 (elpipodect) in 29 people with Alzheimer's disease, some of whom also had symptoms like agitation or psychosis. The main goal was to see if the drug is safe and tolerable at different doses. Researchers tracked side effects and how many people had to stop taking the drug due to problems.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlanta Center for Medical Research ( Site 0004)
Atlanta, Georgia, 30331, United States
-
CITrials ( Site 0007)
Santa Ana, California, 92705, United States
-
Global Medical Institutes LLC; Princeton Medical Institute ( Site 0008)
Princeton, New Jersey, 08540, United States
-
Richmond Behavioral Associates ( Site 0003)
Staten Island, New York, 10314, United States
-
Top Medical Research ( Site 0005)
Cutler Bay, Florida, 33189, United States
-
Velocity Clinical Research, Hallandale Beach ( Site 0001)
Hallandale, Florida, 33009, United States
-
Well Pharma Medical Research, Corp. ( Site 0006)
Miami, Florida, 33173, United States
-
iResearch Atlanta ( Site 0009)
Decatur, Georgia, 30030, United States
Conditions
Explore the condition pages connected to this study.